MITF-siRNA formulation is a safe and effective therapy for human melasma

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 362-371

  Yi, Xiang ^a   Zhao, Guang ^b   Zhang, Hongjie ^a   Guan, Di ^a,c   Meng, Rusong ^b   Zhang, Yingyu ^a   Yang, Qingqi ^b   Jia, Henming ^b   Dou, Kejun ^d   Liu, Chui ^a   Que, Fangyuan ^a   Yin, James Q ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARBUTIN; KOJIC ACID; MELANIN; MELANOCORTIN 1 RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; SMALL INTERFERING RNA; TYROSINASE RELATED PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHLOASMA; COLORIMETRY; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; EPILUMINESCENCE MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOGENESIS; MOUSE; NONHUMAN; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SKIN COLOR;

EID: 79551623112     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.263     Document Type: Article

References (39)

1. Cestari, T, Arellano, I, Hexsel, D and Ortonne, JP; Latin American Pigmentary Disorders Academy (2009). Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol 23: 760-772.
2. Gupta, AK, Gover, MD, Nouri, K and Taylor, S (2006). The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 55: 1048-1065.
3. Parvez, S, Kang, M, Chung, HS, Cho, C, Hong, MC, Shin, MK et al. (2006). Survey and mechanism of skin depigmenting and lightening agents. Phytother Res 20: 921-934.
4. Rafal, ES, Griffiths, CE, Ditre, CM, Finkel, LJ, Hamilton, TA, Ellis, CN et al. (1992). Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med 326: 368-374.
5. Stern, RS (2004). Clinical practice. Treatment of photoaging. N Engl J Med 350: 1526-1534.
6. Torok, HM, Jones, T, Rich, P, Smith, S and Tschen, E (2005). Hydroquinone 4, tretinoin 0.05, fluocinolone acetonide 0.01: a safe and efficacious 12-month treatment for melasma. Cutis 75: 57-62.
7. Draelos, ZD (2007). Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 20: 308-313.
8. Miller, AJ and Mihm, MC Jr (2006). Melanoma. N Engl J Med 355: 51-65.
9. Steingrímsson, E, Copeland, NG and Jenkins, NA (2004). Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 38: 365-411.
10. Tassabehji, M, Newton, VE and Read, AP (1994). Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 8: 251-255.
11. Hemesath, TJ, Steingrímsson, E, McGill, G, Hansen, MJ, Vaught, J, Hodgkinson, CA et al. (1994). microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8: 2770-2780.
12. Vance, KW, Carreira, S, Brosch, G and Goding, CR (2005). Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 65: 2260-2268.
13. McGill, GG, Horstmann, M, Widlund, HR, Du, J, Motyckova, G, Nishimura, EK et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718.
14. McGill, GG, Haq, R, Nishimura, EK and Fisher, DE (2006). c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 281: 10365-10373.
15. Du, J and Fisher, DE (2002). Identification of Aim-1 as the underwhite mouse mutant and its transcriptional regulation by MITF. J Biol Chem 277: 402-406.
16. Du, J, Miller, AJ, Widlund, HR, Horstmann, MA, Ramaswamy, S and Fisher, DE (2003). MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 163: 333-343.
17. Pei, Y and Tuschl, T (2006). On the art of identifying effective and specific siRNAs. Nat Methods 3: 670-676.
18. Leachman, SA, Hickerson, RP, Schwartz, ME, Bullough, EE, Hutcherson, SL, Boucher, KM et al. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18: 442-446.
19. Sibley, CR, Seow, Y and Wood, MJ (2010). Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 18: 466-476.
20. Deshayes, S, Morris, M, Heitz, F and Divita, G (2008). Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 60: 537-547.
21. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57-67.
22. Halder, RM and Richards, GM (2004). Topical agents used in the management of hyperpigmentation. Skin Therapy Lett 9: 1-3.
23. Dynek, JN, Chan, SM, Liu, J, Zha, J, Fairbrother, WJ and Vucic, D (2008). Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 68: 3124-3132.
24. Futaki, S, Suzuki, T, Ohashi, W, Yagami, T, Tanaka, S, Ueda, K et al. (2001). Argininerich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276: 5836-5840.
25. Khalil, IA, Futaki, S, Niwa, M, Baba, Y, Kaji, N, Kamiya, H et al. (2004). Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther 11: 636-644.
26. Won, YW, Kim, HA, Lee, M and Kim, YH (2010). Reducible poly(oligo-D-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol Ther 18: 734-742.
27. Kaspar, RL, McLean, WH and Schwartz, ME (2009). Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International Pachyonychia Congenita Consortium. J Invest Dermatol 129: 2085-2087.
28. Kittler, H, Pehamberger, H, Wolff, K and Binder, M (2002). Diagnostic accuracy of dermoscopy. Lancet Oncol 3: 159-165.
29. Clarys, P, Alewaeters, K, Lambrecht, R and Barel, AO (2000). Skin color measurements: comparison between three instruments: the Chromameter®, the DermaSpectrometer® and the Mexameter®. Skin Res Technol 6: 230-238.
30. Taylor, S, Westerhof, W, Im, S and Lim, J (2006). Noninvasive techniques for the evaluation of skin color. J Am Acad Dermatol 54(5 Suppl 2): S282-S290.
31. Piérard, GE (1998). EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 10: 1-11.
32. Takiwaki, H, Miyaoka, Y, Kohno, H and Arase, S (2002). Graphic analysis of the relationship between skin colour change and variations in the amounts of melanin and haemoglobin. Skin Res Technol 8: 78-83.
33. Sanchez, NP, Pathak, MA, Sato, S, Fitzpatrick, TB, Sanchez, JL and Mihm, MC Jr (1981). Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 4: 698-710.
34. Yin, JQ, Gao, J, Shao, R, Tian, WN, Wang, J and Wan, Y (2003). siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol 3: 194-204.
35. Liu, TG, Yin, JQ, Shang, BY, Min, Z, He, HW, Jiang, JM et al. (2004). Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 11: 748-756.
36. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
37. Chen, Y, Shen, Y, Guo, X, Zhang, C, Yang, W, Ma, M et al. (2006). Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 24: 455-460.
38. Kim, SW, Kim, NY, Choi, YB, Park, SH, Yang, JM and Shin, S (2010). RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release (epub ahead of print).
39. Yin, H, Moulton, HM, Seow, Y, Boyd, C, Boutilier, J, Iverson, P et al. (2008). Cellpenetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918.